HR 5239119th CongressIn Committee

Endometrial Cancer Research and Education Act of 2025

Introduced: Sep 9, 2025

Sponsor: Rep. Scott, David [D-GA-13] (D-Georgia)

EducationHealthcare

Standard Summary

Comprehensive overview in 1-2 paragraphs

The Endometrial Cancer Research and Education Act of 2025 would expand federal attention to endometrial cancer by boosting research and education efforts through the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC). In brief, the bill would: (a) create and fund an NIH program dedicated to expanding and coordinating endometrial cancer research, with a focus on minority disparities and representative participation in clinical trials; (b) require NIH to coordinate with related NIH institutes and offices that oversee minority health and women's health research; and (c) establish a CDC public education program to disseminate information about endometrial cancer—its incidence, risk factors, treatments, and particularly its impact on African-American women. The bill emphasizes addressing racial disparities in incidence and mortality and includes modest funding authorizations for NIH (FY2026–FY2028) and CDC activities (funding “as necessary” for those years). It has been introduced and referred to the House Committee on Energy and Commerce.

Key Points

1Expands NIH research and coordination on endometrial cancer:
2- The NIH Director must expand, intensify, and coordinate endometrial cancer research and inform medical professionals and researchers about disparities and new findings.
3- The NIH must ensure African-American women are represented in endometrial cancer clinical trials in proportion to their incidence rates.
4- Coordination with the Eunice Kennedy Shriver NICHD, the National Institute on Minority Health and Health Disparities, and the Office of Research on Women’s Health is required.
5Public education and awareness through the CDC:
6- The CDC must develop and disseminate public informational materials about endometrial cancer, including incidence, risk factors, minority risk, and treatment options.
7- Materials must include targeted information for African-American women and may be shared with nonprofits, colleges, government entities, or media for broader dissemination.
8- The CDC must consult with HRSA in developing and disseminating materials.
9Funding authorization and spending:
10- NIH section 409K authorizes $1,000,000 for each of fiscal years 2026–2028 to support the new endometrial cancer program.
11- CDC’s new endometrial cancer public education program (Section 399V-8) authorizes appropriations as necessary for FY2026–FY2028.
12Foundational findings guiding the bill:
13- Endometrial cancer is the most common uterine cancer and is the fourth most common cancer in women.
14- The incidence and mortality patterns show disparities, with higher aggressiveness and mortality among African-American women and rising incidence among minority groups.
15- Contributing factors to disparities may include delays in care, late-stage diagnoses, and barriers to accessing innovative treatments.

Impact Areas

Primary group/area affected- African-American women and other ethnic minority women, who are highlighted for higher mortality and certain disparities in endometrial cancer risk and outcomes.- Researchers, clinicians, and trial participants involved in endometrial cancer research.Secondary group/area affected- Broader patient population with endometrial cancer, who could benefit from expanded research, better trial inclusion, and improved education about risk factors and treatments.- Healthcare professionals and public health officials who would receive updated guidance and educational materials.Additional impacts- Increased coordination across NIH institutes and with CDC/HRSA could lead to more integrated federal efforts on endometrial cancer and potentially reduce delays in diagnosis and treatment.- Public education materials may empower patients and communities, particularly African-American women, to seek timely care and participate in clinical research.- The funding levels are modest by NIH standards, so the act would likely serve as a targeted start or pilot effort, potentially prompting further funding in later years if proven effective.

Generated by gpt-5-nano on Oct 8, 2025